Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Midostaurin added to standard therapy in newly diagnosed c-KIT or FLT3-ITD mutated t(8;21) acute myeloid leukemia
2011-002567-17Phase 2Completed
- Sponsor
- Technische Universität Dresden
- Start
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of midostaurin in acute myeloid leukemia (AML), sponsored by Technische Universität Dresden. Primary endpoint: 2-year event-free survival. Started Sep 2011; status: completed.
02
Drugs
midostaurin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2011-002567-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002567-17.